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Abstract 
 
Background: Ghrelin and adiponectin are recently discovered peptides. Ghrelin has a crucial role in 
the regulation of food intake and energy homeostasis, and adiponectin is secreted by adipocytes, and it 
has been proposed to mediate obesity-related insulin resistance. Both they are playing a critical role in 
a variety of physiological processes including endocrine, metabolic, cardiovascular, and other actions. 
Furthermore,  other  potential  clinical  applications  of  ghrelin  include  the  treatment  of  patients  with 
diabetes  mellitus  and  infections,  likewise  adiponectin  plays  an  important  role  in  diagnosis  of 
cardiovascular disease.  
Conclusions:  Further  studies  need  to  specify  the  accurate  results  and  the  action  mechanisms  of 
adiponectin in order to facilitate the clinical practice; as well as to clarify the role of these adding a new 
knowledge in international scientific community.   
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Introduction 
 
Ghrelin  is  a  recently  discovered  hormone, 
with a crucial role in the regulation of food 
intake and energy homeostasis (Korbonits et 
al,  2004).  Ghrelin  levels  increase  before 
meals  and  decrease  after  meals.  It  is 
considered  the  counterpart  of 
the hormone leptin,  produced  by  adipose 
tissue,  which  at  higher  levels  induces 
satiation.  In  some  bariatric 
interventionalprocedures, the level of ghrelin 
is  reduced  thus  causing  satiation  before  it 
would physiologically occur. 
Adiponectin  lipokines  are  hormones 
produced by the adipose tissue. They  were 
detected in early of 90s, and leptin was the 
first member of the family been discovered. 
Before this discovery, the adipose tissue was 
known  as  energy  store  compartment 
regulating  lipid  metabolism  and 
thermogenesis.  Adiponectin  is  an 
approximately  30-kDa  polypeptide,  and 
interestingly,  the  terminal  structure  of  its 
globular domain bears a striking similarity to 
tumor  necrosis  factor-α  (TNF-α),  despite  a 
lack  of  homology  intheir primary sequence 
(Shapiro & Scherer, 1998).
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After  briefly  reviewing  the  physiologically 
relevant  effects  of  the  two  adipose  tissue 
mediators  we  focused  on  the  potential 
mediating  mechanisms  with 
pathophysiological importance on metabolic 
and  cardiovascular  disease  initiation  and 
progression. 
Ghrelin   
Few  peptide  hormones  have  attracted  as 
much  attention  as  ghrelin,  the  natural 
secretagogue  for  growth  hormone  (GH) 
identified by Kojima et al in 1999, resulting 
>4000  PubMed  citations  over  the  last  ten 
years (Kojima et al, 1999).  It was initially 
observed that ghrelin could stimulate feeding 
in  mammals,  and  may  have  clinical 
implications  on  the  development  of 
antiobesity  drugs.  Subsequent  studies  
revealed  the  complexity  of  the  ghrelin 
modulated  mechanisms  including  the 
differential physiological effects of the three 
peptide products of the ghrelin gene: ghrelin, 
which  is  peri-translationally  modified  via 
acylation  with  the  octanoic  acid;  des-acyl 
ghrelin(molecule not-acylatedor orphan from 
its fatty acid residue); andobestatin, another 
bioactive  peptide  derived  from  the  pre-
proghrelin precursor (Fetissov et al, 2010). 
Ghrelin  is  abundantly  synthesized  by 
specialized  mucosal  cells  in  the  stomach 
accounting  for  about  80%  of  the  serum 
ghrelin  production  in  rats  and  for  65%  in 
humans.  Some  ghrelin  producing  cells  are 
also  found  in  lower  parts  of  the 
gastrointestinal  (GI)  tract,  where  ghrelin 
expression could be up-regulated in special 
circumstances (e.g. after gastrectomy). Low 
circulating  levelsof  ghrelin  are  associated 
with obesity, insulin resistance and diabetes 
mellitus type 2 (Sakata et al, 2010; Veldhuis 
& Bowers, 2010). 
Most  importantly,  it  has  beenpostulatedthat 
beyondstimulation of growth hormone (GH) 
secretion and increased feeding, ghrelin has 
multiple  biological  effects.  Over  these 
functions,  ghrelin  was  found  to  regulate 
gastrointestinal  motility,  sensory  functions, 
reproduction,  psychical  sphere,  glucose 
metabolism,  cardiovascular  system  and 
kidneyfunction  (Meyer,  2010;  Schwandt  et 
al, 2010). 
 
Adiponectin 
Adiponectin  or  liponectine  was  detected  in 
1995,  by  four  independent  research  teams 
(Badman & Flier, 2007). It was determined 
initially  in  mice  as  a  protein  expressed  in 
3Τ3-L1 adipose cell-line, and lateron as an 
exclusive  product  of  the  adipocytes’  gene 
apM1 (Maeda et al, 1996; Asmundsdottir et 
al, 2002). Adiponectin is a molecular weight 
30 kDa protein which is produced elusively 
in  white  adipose  tissue,  although  some 
reports  describe also  its  expression  in  grey 
matter  adipose  tissue  in  T37i  cellular  line 
(Roilides  et  al,  2004).The  molecule  of 
human  adiponectin  consists  of  247  amino-
acid residues. Each unilateral of adiponectin, 
presents    4  distinct  regionsin  a  row:  the 
amino-terminal  end  of  protein,  a  variable 
region,  the  region  with  sequence 
proportional to collagen and the terminal end 
of  spherical  carboxyl  (Berg  et  al,  2002; 
Pajvani et al, 2003). 
The  structure  of  adiponectin  receptors  was 
recently detected and both its isomers were 
determined. The first adiponectin’s receptor 
(AdipoR1)  is  mainly  expressed  in  lineate 
muscles,  whereas  its  second  receptor 
(AdipoR2) is  mainly  expressed  in the  liver 
(Krcmery & Barnes, 2002).  
Adiponectin  acts  via  connection  of  its 
molecule  with  the  special  adiponectin   
receptors  on  cells  surface  in  the  main 
target organs:  muscles, liver and vessels 
(Chandran  et  al,  2003).  The  most 
important  adiponectin  functions  so  far, 
are  reflected  through  its  antiathero- 
genetic,  anti-inflammatory  and  tissue 
insulinsensitizing  action  (Torres  et  al, 
2005). 
As concerns the anti-inflammatory effect, it 
was shown that both TNFα and adiponectin 
act at the same target organs with opposing 
effects  (Schoelson  et  al,  2006;  Tilg  & 
Moschen, 2008). The resultingimbalance can 
lead to insulin resistance and perpetuation of 
low  grade  systemic  inflammation 
(Hotamisligil et al, 1995).  
As a sensitizing factor of insulin, adiponectin 
is  linked  to  special  membrane  receptors 
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enzyme  a  carboxylase,  promoting  the 
anaerobic  glycolysis  and  the  oxidation  of 
fattyacids  (Yamauchi  et  al,  2002). 
Additionally strengthens insulin action at the 
liver,  with  beneficial  effects  on  both 
glycaemia and lipaemia (Thamer et al, 2002; 
Gressner  et al, 2007; Ban & Twigg, 2008; 
Kamada et al, 2008).  
Dingetal  showed  that  adiponectin  acts 
inhibitory  for  the  action  of  the  activating 
asteroid  cells  and  therefore,  to  the 
fibrogenesis process  in hepatic parenchyma 
(Ding et al, 2005). This antifibrotic action at 
hepatic  level  it  might  be  processed  via 
inhibition of the connective tissue. 
Correlation between 
adiponectin/ghrelin and growth 
hormone (GH) 
Ghrelin  and  its  receptors  are  produced  in 
almost  all  tissues  including  hypothalamus 
arcuate  nuclei,  pituitary  and  placenta 
(Pomboet  al,  2001;  Broglio  et  al,  2003). 
Ghrelin  affects  GH  secretion  and  it  was 
initially locatedin the stomach as a ligand for 
growth  hormone  secretagogue  (GHS) 
receptor.  Additionally,  ghrelin  exerts  direct 
and  indirect  modulation in  food  intake and 
energy expenditure. 
GH  produced  and  secreted  by  the  anterior 
lobe of the pituitary, promotes the  indirect 
and    along  increase  connected  with  its 
receptor  in  liver  through  the  production  of   
the insulin –like growth factor (IGFI). It has 
been proved that ghrelin participates with the 
GHRH  (Growth  hormone  releasing 
hormone)  and  the  somatostatin  to  the 
regulation  of  the  GH  production  in  the 
pituitary.  Ghrelin  stimulates  direct  GH 
release in vitro from somatotrophs and also 
when  infused  in  vivo,  although  the  latter 
action appears to require the participation of 
an intact GHRH system. Ghrelin stimulates 
GH secretion in a synergistic fashion when 
co-infused  with  GHRH.  Experimental,  in 
vivo and in vitro studies demonstrated strong 
and dose-dependent effect of ghrelin on GH 
secretion (Broglio et al, 2001). 
In humans GH response to ghrelin resists to 
the  external  administration  of  somatostatin 
or cortistatin. Sex-independent GH and GHS 
secretion  by  Ghrelinis  progressively 
diminished  with  aging,  and  it  is  increased 
bypharmaceutical  doses  of  estrogen 
(Seoaneet al, 2000; Whatmore et al, 2002). 
It  was  shown  that  GH  treatment  in  pre-
pubertal  children  decreases  serum 
adiponectin  levels, further correlated to the 
growth  response.  In  a  step  further,  GHD 
(Growth  Hormone  Deficiency)  in 
adolescence  is  associated  with  low 
adiponectin  levels  and  unfavorable  lipid 
metabolism (Lanes et al, 2006). Adiponectin 
levels are significantly lower in patients with 
adult GHD than in patients with acromegaly 
(Fukuda  et  al,  2004).  Adiponectin 
concentration  did  not  differin  patients  with 
GHD  and  healthy  controls,  whereas  in 
patients  with  acromegaly  insulin  resistance 
appears  to  be  not  closely  related  to 
adiponectinemia in dependently of BMI. The 
different  relationship  between  adiponectin 
and  quantitative  insulin  sensitivity  check 
index  (QUICKI)  observed  in  adultswith 
either  GHD  or  acromegaly 
presumablyreflects  differences  in  the 
mechanisms  of  insulin  resistance  under 
states  of  GH  deficiency  or  excess 
(Andersson et al, 2009). 
Effects of ghrelin and adiponectin on 
glucose metabolism 
Clinicalstudies  were  conducted  in  order  to 
study ghrelin’s action on glucose metabolism 
and insulin secretion. However, they didn’t 
reach to safe conclusion, due to the ghrelin’s 
different  actions(sedative  and  inhibitory 
action) to insulin secretion. 
Oral  glucose  tolerancetestingwas 
accompanied  by  significant  suppression  to 
the  increasing  insulin  levels  after  ghrelin’s 
administration.  Thus,  it  seems  that  ghrelin 
inhibits rapidly insulin secretion in humans 
after  intravenous  injection,  despite  high 
glucose levels and by contrastinsulin inhibits 
ghrelin’s  secretion  independently  of  body 
adiposity.  However,  co-administration  of 
ghrelin  and  antagonist  of  the  GH  receptor 
resulted in an increase of insulin resistance 
(Kojima  et  al,  1999;  Murdolo  et  al,  2003; 
Meyer, 2010). 
To date, the role of ghrelin in the regulation 
of  insulin  secretion  remains  controversial, 
possiblybecause  of  differences  in  the 
experimental conditions. Indeed, ghrelin was 
found  to  inhibit  insulin  secretion  in  the International  Journal of  Caring  Sciences  September-December  2013  Vol  6  Issue 3 
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majority  of the studies but alsoto stimulate 
insulin  secretion  in  others.  For  example, 
ghrelin  increased  cytosolic  free  Ca
2+ 
concentrations  in  rat  β-cells  and  increases 
insulin  secretion  in  isolated  rat  pancreatic 
islets  under  hyperglycemic  conditions. 
Furthermore,  ghrelin  increases  insulin 
secretion from the pancreas of both normal 
and  diabetic  rats.  In  contrast,  GHS-R1a 
blockade  by  specific  antagonists  or  ghrelin 
inactivation  using  an  antiserum  enhanced 
glucose-induced  insulin  release  and 
intracellular  Ca
2+  concentrations  in  isolated 
rat  islets.Further,  exogenous  ghrelin 
decreased insulin secretion in isolated mouse 
pancreata,  in  mouse  and  rat  isolated  islets, 
and  in  β-cell  lines  (Kahn  &  Flier,  2000; 
Holdstock  et  al,  2003;  Gauna  et  al,  2004;  
Heppner et al, 2011).  
The  findings  by  Tong  et  al.  provide  clear 
proof  of  concept  that  ghrelin  can  reduce 
glucose-stimulated  insulin  secretion. 
Admittedly, it is possible that ghrelin, due to 
its  local  synthesis  and  release  within  the 
islets  of  Langerhans,  may  reach  very  high 
concentrations  at  the  β-cell  and  act  via  an 
autocrine  and/or  paracrine  rather  than 
systemic  mechanisms.  Furthermore, 
although not observed by Tong et al., ghrelin 
has  been  found  to  increase  plasma 
epinephrine  levels  in  humans,  suggesting 
that it may also inhibit insulin secretion via a 
sympathetic response (Tong et al, 2010). 
Ghrelin’s  action  in  insulin  it  has  been 
alsostudied  in  hepatocytes  inhuman.  It  was 
observed  that  ghrelin  was  activating  the 
insulin receptor type 1 (IRS1) demonstrating   
that ghrelin has a direct anti- insulin effect, 
but indirect effect in gluconeogenesis. 
Finally, ghrelin has a direct effect to glucose 
levels,  leading  to  hyperglycemia. 
Intravenous  injection  of  ghrelin  increases 
glucose  levels  in  humans  (obese  and 
individuals  with  normal  weight).  Ghrelin 
administration  was  accompanied  by 
increased glucose levels not by reduction of 
insulin  because  hyperglycemia  anticipates 
hypoinsulinemia by 15 min (Sun et al, 2007). 
In conclusion, despite conflicting views for 
ghrelin’s action in both  insulin release and 
homeostasis,  glucose  levels  are  modulated 
via:  GH  release,  cortisol,  adrenaline,  and 
probably  glucagon;  enhancementof  insulin 
resistance; activation of gluconeogenesis. 
Studies conducted in guinea pigs and later in 
humans  showed  are  verse  relationships 
between adiponectin and insulin resistance.  
There  after  numerous  studies  were 
performed  to  specifically  investigate  the 
correlation  between  adiponectin  levels  and 
metabolic  syndrome  components  including 
sleep apnea syndrome (Tschritter et al, 2003; 
Iwashimaet  al,  2004;  Nagao  et  al,  2005; 
Farvid et al, 2005).    
Accordingly,  low  adiponectin  levels  were 
detected  in  patients  with  type  2  diabetes 
mellitus (Spranger et al, 2003; Yamauchi et 
al, 2003), dyslipidemia (Farvid et al, 2005), 
hypertension,  and  cardiovascular  disease 
compared  to  their  healthy  counterparts 
(Adamczaket  al,  2003;  Iwashima  et  al, 
2004).  
Gene apM1 was found in chromosome 3q27, 
a locus correlated with metabolic syndrome, 
whereas, apM1polymorphismspromoting the 
inhibition  of  adiponectin  production  were 
identified  in  individuals  with  insulin 
resistance  (Kissebah  et  al,  2000). 
Particularly,  serum  adiponectin 
concentration  in  pre-diabetic  conditions 
determined  the  development  of  type  2 
diabetes  mellitus. By contrast, reduction  of 
body  weight  and  therapy  with 
thiazolidinediones  were  accompanied  by 
increase  of  adiponectin  suggesting  that  the 
latter could be a potent marker of metabolic 
syndrome (Maeda et al, 2001; Mather et al, 
2008). 
Finally,  hypoadiponectinemia  was  found 
correlated  with  conditions  associated  with 
insulin resistance, such as both alcoholic and 
no-alcoholic  adipose  liver  disease  chronic 
hepatitis C, and polycystic ovary syndrome 
(Sato et al, 2005; Youet al, 2005; Tanet al, 
2006; Tsochatzis et al, 2006).  
The  sex-  and  geographical  region-oriented 
differences in adiponectin levels are not yet 
fully  understood,  however,  the  role  of 
androgens or other confounders (e.g. central 
type obesity in men, different level of insulin 
resistance)could  at  least  partly  explain  that 
phenomenon (Combset al, 2003; Isobeet al, 
2005;  Kadowakiet  al,  2006;  Renaldy  et  al, 
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Correlation between 
ghrelin/adiponectin and obesity 
As previously discussed ghrelin has a potent 
orexigenic effect, stimulating AGRP(Agouti-  
Related  Protein),  NPY  (Hypothalamic 
Neurons  Neuropeptide),  orexin  A  and  B. 
Ghrelin counteracts the anorexigenic effects 
of  leptin  at  central  nervoussystem  (CNS). 
Ghrelin’s  levels  reach  their  peak 
concentration during fasting, whereas caloric 
intake produces a fall  in the serum ghrelin 
(Pinkney & Williams, 2002). 
It  is  proved  that  externally  administrating 
high  levels  of  ghrelin  can  cause  stable 
increase of food intake, leading to increasing 
weight.  The  secretion  rate  makes  ghrelin 
responsible  for  the  immediate  increase  of 
thesense of hungry, given that it is increased 
in the highest levels few minute before the 
meal  and  is  decreased  in  the  lowest  levels 
after the end of the meal (Cummings et al, 
2002;  Shiiyaet  al,  2002).  Obesity  is 
connected  with  low  levels  of  ghrelin  in 
plasma,  whereas  the  anorexia  nervosa  is 
associatedwith high levels. 
It  stimulates  pre-adipocyte  differentiation, 
increases  the  body  fat  and  inhibits  the 
anorexigenic  effect  of  leptin.  After  gastric 
bypass  surgery,  ghrelin’s  levels  are  staidly 
reduced  with  simultaneous  disorder  of  the 
secretion rate. The latter might beattributed 
to thelossof important number of gastric cells 
which  produce  the  hormone.  In  case  of 
bulimia,  ghrelin’s  levels  were  found  to  be 
increased even in persons with normal body 
mass,  probably  due  to  abnormal  habits  of 
food  intake,  putting  the  suspicion  for 
participation  of  ghrelin  to  this  disorder 
(Caminoset al, 2002; Cummings et al, 2002). 
In patients with cachexia the administration 
of ghrelin is correlated with increasing food 
intake andsimultaneous weightgain (Nagaya 
et  al,  2001; Tanaka  et  al,  2002).  It  is  also 
observed that ghrelin’s levels are increased 
in hypothyroidism,  whereas their levels are 
decreased in hyperthyroidism (Caminoset al, 
2002). 
Adiponectin  serum  levels  are  significantly 
reduced  in  central  obesity.  Although  the 
adiponectin  is  produced  exclusively  by  the 
antipocytes,  mechanisms  of  negative 
regression  feedback,  cause  reduction  of  its 
concentration  in  obesity,  unlike  the  other 
adiponectines (Nagaya  et al, 2001; Berg  et 
al, 2002; Cnop  et al, 2003; Takemuraet al, 
2007; Komura et al, 2010).
 
Correlation  between ghrelin/  adiponectin 
and cardiovascular diseases 
 
Ghrelin’s  receptors  have  been  isolated  in 
whole  cardiovascular  system.  Their 
concentration  found  increased  in  patients 
with atherosclerosis, coronary heart disease 
and  other  vascular  diseases.  External 
administration  of  ghrelin  in  patients  with 
congestive  heart  was  accompanied  by 
reduction of arterial blood pressure (Kojima 
&  Kangawa,  2005;  Zhang  et  al,  2010), 
increase of cardiac index and stroke volume 
without  changes  in  the  mean  pulmonary 
pressure.  Beneficial  results  such  as 
improvement  of  left  ventricular  function 
were also documented in animal models due 
to  the  reduction  of  peripheral  arterial 
resistance. 
Increased  accumulation  of  the  des-acyl 
ghrelin (inactive form  of the  hormone) but 
not of the total ghrelin in plasma, it observed 
also  in  patients  with  renal  failure.  This 
increase is connected with creatinine levels. 
Accordingly, the kidneys have an important 
role to the clearance and metabolism of des-
acyl ghrelin.  
In the course  of normal pregnanciesghrelin 
levels  are  negatively  correlated  with  blood 
pressure,  whereas  in  hypertensive 
pregnancies ghrelin levels are high (Bodartet 
al,  1999;  Iglesiaset  al,  2004;  Zhang  et  al, 
2010). 
As  previously  discussed  ghrelin 
administration  is  associated  with  decreased 
systemic  vascular  resistance  whereas 
increases the cardiac output in patients with 
heart failure and   in healthy individuals and 
improves the heart structure and function. In 
animal  models  of  heart  failure,  ghrelin 
administration improves cardiac contractility 
and  attenuates  the  development  of  cardiac 
cachexia. 
Recent  studies  demonstrated  the  anti-
apoptotic effect of ghrelin  in  myocardium 
cells  in  the  context  of  both  ischemic  heart 
failure  and  anthracycline-induced 
cardiomyopathy.  Additionally,  ghrelin International  Journal of  Caring  Sciences  September-December  2013  Vol  6  Issue 3 
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attenuates  atherosclerotic  progression,  both 
by  modulation  of  inflammatory  processes 
and  by  inhibition  of  leucocytes 
chemoattractant properties.  
These  effects  might  mediate  the  possible 
protective  role  of  ghrelin  and  its  synthetic 
secretagogoues  on  cardiovascular  system 
(Muccioli  et  al,  2000;Wiley  &  Davenport, 
2002; Cao et al, 2006).
 
At present many clinical studies indicate that 
adiponectin  could  have  a  protective  effect 
against  the  development  of  cardiovascular 
diseases  (Frystyk  et  al,  2007)  through  its 
anti-inflammatory effects. In vivo studies in 
mice  confirmed  the  anti-atherogenic 
properties  of  adiponectin  previously 
(Matsuda et al, 2002; Verma et al, 2004). 
Adiponectin  deficient  mice  demonstrated 
enhanced  thrombus  formation  and  platelet 
aggregation  at  sites  of  vascular  injury  as 
compared with their controlled counterparts 
(Kato  et  al,  2006)  suggesting  that 
adiponectin  may  possess  potential 
antithrombotic properties.  
Adiponectin  has  also  been  shown  to: 
stimulate the productionof nitric oxide (NO) 
in  vascular  endothelial  cells;  inhibitthe 
expression  of  adhesion  molecules;  inhibit 
class  A  scavengerreceptor  expression  in 
macrophages;  and  inhibit  proliferationand 
migration  of  human  aortic  smooth  muscle 
cells  (Hug  &  Lodish,  2005;  Trujillo  & 
Scherer, 2005). 
Hypoadiponectinemia  appears  to  be 
associated  with  peripheral  arterial  disease. 
Low  plasma  levels  of  adiponectin  were 
associated with the presence of symptomatic 
peripheral  arterial  disease,  independent  of 
traditional  risk  factors  (Dieplinger  et  al, 
2006).  However,  the  same  inverse 
relationship was not detected in patients with 
chronic heart failure. Low concentrations of 
adiponectin appear to be associated also with 
an early onset of coronary heart disease and 
the  presence  of  multiple  atherosclerotic 
lesions on coronary arteries. 
The  association  of  hypoadiponectinemia 
with atherosclerotic disease extends beyond 
the  coronary  vasculature.  In  a  case-control 
study  among  individuals  with  or  without 
ischemic  
 
cerebrovascular  disease,  decreasing 
concentrations  of  adiponectin  were 
independently  and  significantly  associated 
with  a  higher  risk  of  stroke  (Chen  et  al, 
2003). 
Lower concentrations of plasma adiponectin 
have  also  been      associated  with  both 
essential  hypertension  and  dyslipidemia. 
Patients  with  essential  hypertension  appear 
to have significantly lower levels of plasma 
adiponectin  compared  to  normotensive 
patients. 
A correlation between adiponectin and HDL-
cholesterol,  triglycerides  and  NT-pro  brain 
natriuretic peptide(BNP), was also observed 
after  adjustment  for  multiple  confounders 
suggesting  that  dyslipidemia  could  be  an 
intermediate  link  between  adiponectin  and 
atherosclerosis  progression  (Chen  et  al, 
2003; Shibata et al, 2004; Dieplinger et al, 
2006). 
Adiponectin “paradox” in the setting of heart 
failure (HF) progression: in HF the increase 
of  the  adiponectin  levels,  associated  to  the 
decrease in body weight, have not the waited 
cardiovascular  protective  actions.  High 
adiponectin levels act as indicators of disease 
severity,  but  its  function  as 
pathophysiological mediator is less relevant 
in this situation suggesting the existence of a 
“functional adiponectin resistance” in HF. 
Adiponectin  may  serve  to  limit  cardiac 
remodeling, which leads to hypertrophy and 
diastolic  dysfunction, as well as to provide 
protection  from  ischemic  damage.  In 
adiponectin  deficient  mice,  pressure 
overload  resulted  in  enhanced  concentric 
cardiac hypertrophy and increased mortality 
compared  to  control  mice  (Shibata  et  al, 
2004).  
Conclusions 
An  initial  interest  about  ghrelin  can  be 
attributed  to  the  ability  of  ghrelin  to 
stimulate feeding in mammals suggesting it 
as a potential target for the development of 
anti-obesity  drugs.  It  has  been  also  proved 
that  ghrelin  participates  with  the  GHRH 
(Growth  hormone  releasing  hormone)  and 
the somatostatin to the regulation of the GH 
production   in   the  pituitary.  Ghrelin  is  an  International  Journal of  Caring  Sciences  September-December  2013  Vol  6  Issue 3 
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important factor influencing growth hormone 
release during pregnancy too. 
The integrative role of ghrelin in homeostatic 
regulation is evident from its function in the 
regulation  of   reproduction versus   feeding.  
Ghrelin  inhibits  the  activity  of  the 
hypothalamic-pituitary-gonadal  axis  acting 
both  centrally  and  peripherally,  similar  to 
hypothalamic neuropeptide Y (NPY), and a 
down-stream  target  of  ghrelin.  It  has  been 
found to increase plasma epinephrine levels 
in  humans,  suggesting  that  it  may  also 
inhibit  insulin  secretion  via  a  sympathetic 
response. 
The  ghrelin receptors density concentration 
has  found  increased  in  patients  with 
atherosclerosis,  coronary  heart  disease  and 
other vascular diseases. It has also found that 
the  external  administration  of  ghrelin  in 
patients with congestive heart disease caused 
positive effects, as reduction of arterial blood 
pressure without changes of cardiac rate. The 
adipose tissue does not only store excess of 
energy,  but  adipokines  also,  which  are 
responsible  directly  and  indirectly  for  the 
cardiac homeostasis. The adiponectin has a 
role of mediator in insulin’s action as well as 
a  strong  ant  inflammatory  and  anti 
atherogenic action. 
The  majority  of  studies  have  shown  the 
adiponectin’s  serum  concentration  is  a 
biological  base  of  diabetes  prevention  as 
well  as  dyslipidemia,  hypertension,  which 
are  significant  factors  for  cardiovascular 
disease. The sex, age, nationality, the central 
obesity  hereditary  factors  affect 
adiponectin’s concentration levels, which are 
inversionally  associated  with  the  adipose 
mass and the insulin resistance. Its action to 
the  central  nervous  system  increases  the 
energy expenditure and fatty acids oxidation. 
Further  studies  will  specify  the  accurate 
results  and  the  action  mechanisms  of 
adiponectin in order to facilitate the clinical 
practice. Further studies also are needed to 
clarify the role of these peptides and to add a 
new  knowledge  in  international  scientific 
community.  
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